EAS Newsletter February 5, 2024

Governance:

Last call for Young Investigator Awards nominations!

With the annual Young Investigator Awards for outstanding publications, EAS acknowledges excellence that significantly contributes to advancing knowledge in the field of atherosclerosis and associated metabolic disturbances.

Only a few hours remain for nominations! Make your submission now:

Governance:

Be part of the EAS Community and submit your nominations for the EAS Executive Committee elections

Having completed your document verification and updated your EAS membership, the next crucial step awaits – shaping the future of our society by submitting your nominations for the EC Elections.

We invite all EAS full individual members to nominate candidates for positions on the Executive Committee that will be vacant in January 2025.

Click the corresponding buttons below to access the relevant nomination forms for the following roles:

Please note! You need to sign in to access the nomination forms.

Officer positions:

Ordinary Members:

Education:

Join the upcoming class of the Young Fellows Programme for 2025-2026

We open a new class for Young Fellows every other year. This is your chance to join Class 2025-2026, with the first group meeting scheduled for December 2024.

The call for applications is open from February 6 to February 24, 2024.

Ensure you have prepared all the required documents:

• Titles of one or more publications you have authored in the field of atherosclerosis research
• Short CV
• A letter of motivation

Note that applicants must be 40 years or younger by December 31, 2023.

If you meet the criteria, please fill out the form below:

Please note! You need to sign in to access the application form.

Education:

Save the date and register for our upcoming webinar on “Women and cardiovascular health”!

Join us for an insightful webinar delving into the intricacies of women’s cardiovascular health. Explore specific risk factors, symptoms, and tailored prevention strategies for the female population.

Act quickly, as seats are filling up fast and gain valuable insights and practical knowledge that can positively impact women’s cardiovascular well-being. Don’t miss out – register now!

Outreach:

New European project aims to improve tools and advice to prevent chronic liver illnesses

GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Supported by the Innovative Health Initiative Joint Undertaking (IHI JU), the consortium will focus on developing the GRIPonMASH Diagnostic Platform which will allow early detection of patients with MASH, better patient stratification and personalized lifestyle advice.

Thirty percent of the world population suffers from Steatotic Liver Disease of which MASLD is one of the clinical presentations. Of these patients, about one in five will develop MASH, an advanced stage of MASLD in which liver inflammation occurs and the liver becomes severely damaged.

Moreover, five percent will develop fibrotic MASH (liver scarring). Whilst MASLD is reversible, MASH and especially fibrotic MASH lead to irreversible complications and could even lead to liver decompensation or liver cancer.

It is expected that by 2030, MASH will be the leading cause of liver transplants worldwide. Early detection of the disease is vital to ensure that the burden of care is lowered, and that patients can recover from MASH before it becomes chronic or even fatal.

We are proud to be one of the partners involved in this project. Please refer to the complete press release for more details about GRIPonMASH diagnostic platform.